← Leaderboards
Mark R Albertini
University Of Wisconsin Madison
$1,770,800
Attributed
$1,770,800
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $653.7K · FY2006–23$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$1,770,800 · 7
VA$0 · 1
By mechanism
K12$1,528,947 · 1
M01$241,853 · 6
I01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Paul M Sondel$16,210,986
- Robert T Striker$387,957
- James A Stewart$6,121,809
- Eric A. Johnson$9,478,846
- Brad Kahl$3,632,482
Others in their field
Top investigators on “Melanoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$206,517,726
- Richard L Schilsky · University Of Chicago$108,377,382
- Larry Arthur$59,113,709
- Charles A Coltman · Southwest Oncology Group$55,198,633
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$47,956,689
- Meenhard Herlyn · University Of Pennsylvania$46,448,742
Research focus
MelanomaClinical ResearchTumorHuman SubjectFutureNeoplasm /Cancer ImmunotherapyHuman Therapy EvaluationDesignRadiation TherapyClinical Trial Phase IMonitorInterleukin-2VaccinesMetastatic MelanomaImmunePeripheral BloodDoseChimeric ProteinsAnti-Cancer TherapeuticClinical AssessmentsAutologousBlood VesselsAntitumor ResponseCanis Familiaris
Grant awards (19)
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma$0
I01 · FY2023 · VA · contact PI
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma$0
I01 · FY2022 · VA · contact PI
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma$0
I01 · FY2022 · VA · contact PI
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma$0
I01 · FY2020 · VA · contact PI
Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma$0
I01 · FY2019 · VA · contact PI
Clinical Academic Oncologist Training Program$446,225
K12 · FY2008 · CA · contact PI
Clinical Academic Oncologist Training Program$651,256
K12 · FY2007 · CA · contact PI
HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 & IFN IN MELANOMA$1,685
M01 · FY2007 · RR · contact PI
VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA$770
M01 · FY2007 · RR · contact PI
Clinical Academic Oncologist Training Program$431,466
K12 · FY2006 · CA · contact PI
HIGH-DOSE IFN-ALPHA-2B VS CISPLATIN, VINBLASTINE, DTIC + IL-2 & IFN IN MELANOMA$10,240
M01 · FY2006 · RR · contact PI
VACCINE THERAPY AND/OR GM-CSF IN LOCALLY ADVANCED OR METASTATIC MELANOMA$3,103
M01 · FY2006 · RR · contact PI
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T$106,600
M01 · FY2002 · RR
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T$106,600
M01 · FY2001 · RR
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T$12,855
M01 · FY2001 · RR
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T$0
M01 · FY2000 · RR
IMMUNIZATION USING PARTICLE MEDIATED TRANSFER OF GENES$0
M01 · FY2000 · RR
IMMUNIZATION USING PARTICLE MEDIATED TRANSFER OF GENES$0
M01 · FY2000 · RR
PHASE I/IB TRIAL OF HU14 18 IL 2 FUSION PROTEIN IN PATIENTS W/ GD2+ T$0
M01 · FY2000 · RR